Eye Melanoma Drug
Eye Melanoma Drug

Global Eye Melanoma Drug Market 2019:Quantitative Analysis By Johnson & Johnson Services, Inc, , Carl Zeiss AG, Optovue, Incorporated, Siemens, Koninklijke Philips N.V, Castle Biosciences, Inc, Spectrum Pharmaceuticals, Inc, Gilead Sciences, Inc and others.

Global eye melanoma drug market is expected to grow at a substantial CAGR of in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the increasing prevalence of the eye cancer, growing geriatric population, development in the healthcare expenditure and the government support for the research & development for new and better treatment have fueled the market growth.

Key market players in the global eye melanoma market are Merck & Co., Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc, Sanofi, AbbVie Inc, Amgen Inc, AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Johnson & Johnson Services, Inc, , Carl Zeiss AG, Optovue, Incorporated, Siemens, Koninklijke Philips N.V, Castle Biosciences, Inc, Spectrum Pharmaceuticals, Inc, Gilead Sciences, Inc and others.

Download FREE PDF Sample Copy of Report https://databridgemarketresearch.com/request-a-sample/?dbmr=global-eye-melanoma-drug-market

Market Drivers

  • Increasing prevalence of the eye cancer is the factor driving the market growth
  • Rising healthcare expenditures in developing countries also acts as a driver for this market.
  • Growing geriatric population can also boost the market growth
  • Increasing research and development investments in the field of ocular cancer by the major players of the market is also driving the growth of this market

Market Restraints

  • Lack of awareness amongst people about eye melanoma is restricting the growth of the market
  • High cost of diagnostics, and surgical procedures for eye melanoma can also hamper the growth of this market
  • Less number of approved drugs for eye melanoma acts as a market restraint
  • Long approval time for the drugs is hindering the market growth

Table Of Content:

Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Market Landscape

Part 04: Market Sizing

Part 05: Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape
Part 08: Geographic Landscape

Part 09: Decision Framework
Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Get detailed toc @  https://databridgemarketresearch.com/toc/?dbmr=global-eye-melanoma-drug-market

Segmentation: Global Eye Melanoma Drug Market

By Infected Site

  • Sclera
  • Retina
  • Uvea
    • Iris
    • Choroid Layer
    • Ciliary body

By Diagnosis

  • Eye Exam
  • Eye Ultrasound
  • Angiogram
  • Optical Coherence Tomography
  • Biopsy

By Treatment

  • Radiation Therapy
  • Laser Treatment
  • Photodynamic Therapy
  • Cryotherapy
  • Surgery

By Mechanism of Action

  • Targeted drugs
  • Immunotherapy drugs

By Drugs Type

  • Pembrolizumab
  • Ipilimumab
  • Dacarbazine
  • Temozolomide

By Route of Administration

  • Oral
  • Topical
  • Intravenous
  • Others

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • U.K.
    • France
    • Spain
    • Netherlands
    • Belgium
    • Switzerland
    • Turkey
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Singapore
    • Malaysia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Rest of South America
  • Middle East & Africa
    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In February 2019, Provectus Company received Orphan Drug designation from the US FDA for PV-10, a small molecule oncolytic immunotherapy, for the treatment of eye melanoma including all melanoma disease affecting the eye and orbit. Intratumoral injection of small molecule oncolytic immunotherapy PV-10 can induce immunogenic cell death in solid tumors and stimulate tumor-specific reactivity in circulating T cells. Orphan Drug designation status provides benefits to the company that include seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials and waiver of certain administrative fees
  • In March 2017, Aura Biosciences, Inc received Fast Track designation from the US FDA for AU-011, an investigational new molecule for the treatment of eye melanoma. This is a different class of treatment which has the tendency of selectively destroying the cancer cells using a light-activated viral nanoparticle .Currently very few treatments are available for eye melanoma, these treatments destroy the tumor cells effectively but partial or complete vision loss may occur. but AU-011 has a potential of being a safe and novel therapeutic option that can improve the outlook of the patients

Competitive Analysis:

Global eye melanoma drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of eye melanoma drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

About DataBridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Corporatesales@databridgemarketresearch.com

 

 

About Data Bridge Market Research 10929 Articles
Hi, I am Ravi Kumar, a Blogger, Freelancer, SEO Consultant, an Internet Marketer, I am a research analyst who loves to evaluate data relating to Manufacturing industry, Management of companies and enterprises, Finance and insurance, Wholesale trade, Management, scientific, and technical consulting services

Leave a Reply

Your email address will not be published.


*